4D MOLECULAR THERAPEUTICS IN (FDMT) Forecast, Price Target & Analyst Ratings

NASDAQ:FDMT • US35104E1001

Current stock price

9.4 USD
-0.21 (-2.19%)
At close:
9.39 USD
-0.01 (-0.11%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for 4D MOLECULAR THERAPEUTICS IN (FDMT).

Forecast Snapshot

Consensus Price Target

Price Target
$31.73
+ 237.59% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
May 7, 2026
Period
Q1 / 2026
EPS Estimate
-$1.01
Revenue Estimate
5.27M
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
82.35%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$31.73
Upside
+ 237.59%
From current price of $9.40 to mean target of $31.73, Based on 17 analyst forecasts
Low
$17.17
Median
$33.66
High
$47.25

Price Target Revisions

1 Month
-3.53%
3 Months
-6.04%

Price Target Summary

17 Wall Street analysts provided a forecast for the next 12 months for FDMT. The average price target is 31.73 USD. This implies a price increase of 237.59% is expected in the next year compared to the current price of 9.4.
The average price target has been revised downward by 6.04% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

FDMT Current Analyst RatingFDMT Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6 8

Analyst Ratings History

FDMT Historical Analyst RatingsFDMT Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 5 10 15

Analyst Ratings Consensus

ChartMill Buy Consensus
82.35%
FDMT was analyzed by 17 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about FDMT.
In the previous month the buy percentage consensus was at a similar level.
FDMT was analyzed by 17 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-03-20HC Wainwright & Co.Reiterate Buy -> Buy
2026-03-19Chardan CapitalMaintains Buy -> Buy
2026-03-19RBC CapitalMaintains Outperform -> Outperform
2026-01-28BarclaysInitiate Overweight
2025-12-18Chardan CapitalMaintains Buy -> Buy
2025-11-11Chardan CapitalMaintains Buy -> Buy
2025-11-11RBC CapitalMaintains Outperform -> Outperform
2025-11-11BarclaysMaintains Overweight -> Overweight
2025-10-21RBC CapitalReiterate Outperform -> Outperform
2025-08-12Chardan CapitalMaintains Buy -> Buy
2025-08-12Roth CapitalMaintains Buy -> Buy
2025-08-01Chardan CapitalMaintains Buy -> Buy
2025-07-03Chardan CapitalMaintains Buy -> Buy
2025-05-09Chardan CapitalMaintains Buy -> Buy
2025-05-09BarclaysMaintains Overweight -> Overweight
2025-05-09Goldman SachsMaintains Buy -> Buy
2025-03-10B of A SecuritiesMaintains Buy -> Buy
2025-03-04Chardan CapitalMaintains Buy -> Buy
2025-03-03RBC CapitalMaintains Outperform -> Outperform
2025-03-03HC Wainwright & Co.Reiterate Buy -> Buy
2025-02-11Chardan CapitalMaintains Buy -> Buy
2025-02-10HC Wainwright & Co.Reiterate Buy -> Buy
2025-01-13Leerink PartnersMaintains Outperform -> Outperform
2025-01-13Morgan StanleyMaintains Underweight -> Underweight
2025-01-13HC Wainwright & Co.Reiterate Buy -> Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date
May 7, 2026
Period
Q1 / 2026
EPS Estimate
-$1.01
Revenue Estimate
5.27M
Revenue Q2Q
37,542.86%
EPS Q2Q
-17.68%
Number of Analysts
11

Next Earnings Revisions

Revenue (1 Month)
-35.42%
Revenue (3 Months)
-35.42%
EPS (1 Month)
-6.31%
EPS (3 Months)
-6.31%

Next Earnings Summary

FDMT is expected to report earnings on 5/7/2026. The consensus EPS estimate for the next earnings is -1.01 USD and the consensus revenue estimate is 5.27M USD.
The next earnings revenue estimate has been revised downward by 35.42% in the past 3 months. Downward revisions are a negative sign and indicate that analysts are more pessimistic about the next earnings compared to 3 months ago.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
FDMT revenue by date.FDMT revenue by date.
20.723M
562.08%		37K
-99.82%		85.209M
230,194.59%		9.034M
-89.40%		15.383M
70.28%		46.774M
204.06%		120.19M
156.96%		262.51M
118.41%		495.76M
88.85%		779.99M
57.33%		1.261B
61.67%
EBITDA
YoY % growth
FDMT ebitda by date.FDMT ebitda by date.
-108.663M
-0.96%		-183.188M
-68.58%		-154.853M
15.47%		-274.808M
-77.46%		-323.899M
-17.86%		-375.453M
-15.92%		N/AN/AN/AN/AN/A
EBIT
YoY % growth
FDMT ebit by date.FDMT ebit by date.
-112.867M
-2.58%		-187.841M
-66.43%		-159.547M
15.06%		-247.639M
-55.21%		-278.866M
-12.61%		-371.2M
-33.11%		-352.549M
5.02%		-256.02M
27.38%		-89.294M
65.12%		127.88M
243.21%		536.31M
319.39%
Operating Margin
FDMT operating margin by date.FDMT operating margin by date.
-544.65%-507,678.38%-187.24%-2,741.19%-1,812.82%-793.60%-293.33%-97.53%-18.01%16.40%42.53%
EPS
YoY % growth
FDMT eps by date.FDMT eps by date.
-2.64
20.48%		-2.98
-12.88%		-2.42
18.79%		-3.99
-64.94%		-3.93
1.49%		-4.24
-7.87%		-3.66
13.67%		-2.48
32.31%		-0.91
63.10%		1.67
282.89%		6.98
317.07%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26
EPS
Q2Q % growth		-1.01
-17.68%		-1.00
-1.88%		-1.00
1.48%		-0.98
-327.46%
Revenue
Q2Q % growth		5.27M
37,542.86%		5.27M
35,033.33%		5.27M
5,755.56%		5.27M
-93.81%
EBITDA
Q2Q % growth		-64.097M
-21.93%		-66.031M
-15.36%		-67.436M
-16.86%		-70.439M
-462.92%
EBIT
Q2Q % growth		-67.873M
-26.58%		-69.638M
-17.13%		-71.314M
-16.55%		-73.984M
-602.78%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

FDMT Yearly Revenue VS EstimatesFDMT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
FDMT Yearly EPS VS EstimatesFDMT Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4 -4 6

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
-20.57%
EPS Next 5 Year
-3.39%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
80.98%
Revenue Next 5 Year
105.54%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
-20.30%
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

4D MOLECULAR THERAPEUTICS IN / FDMT Forecast FAQ

Can you provide the average price target for 4D MOLECULAR THERAPEUTICS IN stock?

17 analysts have analysed FDMT and the average price target is 31.73 USD. This implies a price increase of 237.59% is expected in the next year compared to the current price of 9.4.

When does 4D MOLECULAR THERAPEUTICS IN (FDMT) report earnings?

4D MOLECULAR THERAPEUTICS IN (FDMT) will report earnings on 2026-05-07.

Can you provide the consensus estimates for 4D MOLECULAR THERAPEUTICS IN next earnings?

The consensus EPS estimate for the next earnings of 4D MOLECULAR THERAPEUTICS IN (FDMT) is -1.01 USD and the consensus revenue estimate is 5.27M USD.

Can you provide the analyst count for 4D MOLECULAR THERAPEUTICS IN stock?

The number of analysts covering 4D MOLECULAR THERAPEUTICS IN (FDMT) is 17.